Prolia (Denosumab) vs Tymlos (Abaloparatide): Head-to-Head Efficacy for Women With Osteoporosis

Why Comparing These Two Drugs Is Genuinely Complicated

There is no published randomized trial that puts Prolia and Tymlos in the same study and measures who fractures less. That gap matters. When you read claims that one drug is "better" than the other, those claims almost always rest on cross-trial comparisons between studies with different patient populations, different follow-up durations, and different fracture definitions. This article lays out what the actual trial data says, where the extrapolation starts, and how your own life stage and bone history should shape the conversation with your clinician.

How Each Drug Works

Prolia (denosumab) is an antiresorptive. It blocks RANK ligand, a protein that tells osteoclasts (the cells that break down bone) to activate. Less osteoclast activity means slower bone breakdown. Your bone density tends to rise steadily while you take it, and the drug effect wears off within about six months of each missed or stopped dose.

Tymlos (abaloparatide) is an anabolic agent, meaning it stimulates new bone formation rather than simply slowing destruction. It is an analog of parathyroid hormone-related protein (PTHrP). Daily injections trigger osteoblast activity first, before osteoclast activity catches up, which produces genuine structural gains in trabecular and cortical bone. The anabolic window is capped at 24 months lifetime by the FDA label; after that, you need a follow-on antiresorptive to preserve what you built.

Mechanism Shapes Who Gets Which Drug

Women who have already tried and tolerated a bisphosphonate, or who need long-term continuous therapy without a stopping clock, often end up on Prolia. Women with very low bone mineral density (BMD), multiple prevalent vertebral fractures, or who are at imminent fracture risk are more likely candidates for Tymlos first, because anabolic therapy builds new bone architecture rather than just slowing existing bone loss.

The FREEDOM Trial: Denosumab's Key Evidence

The FREEDOM trial enrolled 7,868 postmenopausal women aged 60 to 90 with a T-score between minus 2.5 and minus 4.0 at the lumbar spine or total hip. Women received either 60 mg denosumab subcutaneously every 6 months or placebo for 3 years.

Primary and Secondary Fracture Outcomes

The trial reported a 68% relative risk reduction in new vertebral fractures (7.2% placebo vs. 2.3% denosumab; p < 0.001). Hip fracture risk fell by 40% (0.7% placebo vs. 0.4% denosumab; p = 0.04). Nonvertebral fracture risk dropped by 20% (8.0% vs. 6.5%; p = 0.01).

BMD Gains in FREEDOM

Lumbar spine BMD increased by approximately 9.2% from baseline at 36 months with denosumab, compared with a 1% loss in the placebo group. Total hip BMD rose by about 6.0% versus a slight decrease with placebo.

Who Was in the Trial

The FREEDOM population was entirely postmenopausal. Mean age was 72 years. Women with a T-score below minus 4.0 were excluded, as were those with prior nonvertebral fracture in certain sites, meaning results may not fully generalize to younger postmenopausal women or those with the most severe baseline disease.

The ACTIVE Trial: Abaloparatide's Key Evidence

The ACTIVE trial enrolled 2,463 postmenopausal women aged 49 to 86 with a T-score between minus 2.5 and minus 5.0 at the lumbar spine or femoral neck, or a T-score of minus 2.0 or lower with a radiographic vertebral fracture. Women received abaloparatide 80 mcg daily, teriparatide 20 mcg daily, or placebo by subcutaneous injection for 18 months.

Primary and Secondary Fracture Outcomes

The ACTIVE trial reported an 86% relative risk reduction in new vertebral fractures with abaloparatide versus placebo (4.2% vs. 0.58%; p < 0.001). Major nonvertebral fractures fell by 43% with abaloparatide versus placebo (4.7% vs. 2.7%; p = 0.049). Wrist fracture specifically showed a statistically significant 50% reduction.

The ACTIVExtend Data

Women who completed ACTIVE and then received alendronate for 24 additional months showed further gains and fracture reduction, which is critical clinical context: the anabolic effect of Tymlos is durable only if you follow it with an antiresorptive.

Teriparatide Arm Comparison (Within ACTIVE)

Within the ACTIVE trial itself, abaloparatide produced larger BMD gains at the total hip at 18 months compared with teriparatide, and showed a numerically lower rate of hypercalcemia. This within-trial comparison is direct and valid, unlike any Prolia-versus-Tymlos comparison, which remains cross-trial only.

Cross-Trial Efficacy: What the Numbers Actually Let You Conclude

Because no head-to-head trial exists, clinicians and patients must think carefully about what cross-trial comparisons can and cannot tell you. The framework below organizes what is known versus what is inferred.

| Outcome | Prolia (FREEDOM, 36 mo) | Tymlos (ACTIVE, 18 mo) | Caution | |---|---|---|---| | Vertebral fracture RRR | 68% | 86% | Different durations, different baseline T-scores | | Hip fracture RRR | 40% | Not statistically significant | ACTIVE was not powered for hip fracture | | Nonvertebral fracture RRR | 20% | 43% | Different endpoint definitions | | Lumbar spine BMD gain | ~9.2% at 36 mo | ~9.2% at 18 mo | Abaloparatide gains appear faster | | Total hip BMD gain | ~6.0% at 36 mo | ~3.6% at 18 mo | Prolia numerically larger at 3 years |

What you can say with confidence: Tymlos produces faster BMD gains at the lumbar spine over a shorter window. Prolia shows more durable hip BMD increases over a longer treatment course. Neither superiority claim is validated by a direct randomized comparison.

What you cannot say: That one drug is categorically more effective than the other for reducing fractures in an individual woman, because the trials enrolled slightly different populations and ran for different lengths of time.

Sex-Specific Physiology: Why Hormonal Status Changes Everything

Osteoporosis is overwhelmingly a women's disease. Women account for approximately 80% of the 10 million Americans with osteoporosis, and the rate of bone loss accelerates sharply in the first 5 to 7 years after menopause due to estrogen withdrawal. Both FREEDOM and ACTIVE enrolled exclusively postmenopausal women, so the evidence base is female-specific, which is relatively rare in clinical trial history and a genuine strength of the osteoporosis literature.

Perimenopause

Neither Prolia nor Tymlos is approved for perimenopausal women as a first-line agent. Perimenopausal bone loss is real but typically addressed first with lifestyle measures, calcium (1,000 to 1,200 mg daily from diet and supplement combined), vitamin D (800 to 1,000 IU daily), and menopausal hormone therapy if indicated. Women in perimenopause with a T-score already below minus 2.5 or with a significant fracture history may qualify for pharmacologic treatment earlier; that decision belongs with a clinician experienced in bone health.

Early Postmenopause (Ages 45 to 60)

This is the period of fastest bone loss. The Menopause Society's 2023 position statement on osteoporosis acknowledges that hormonal therapies can preserve bone, but antiresorptives and anabolics become the standard of care when T-scores cross the treatment threshold or fracture risk is high on FRAX.

Tymlos may be particularly appealing in early postmenopause with very low BMD because building new bone in your 50s gives you more structural reserve for the decades ahead. The 24-month limit means you need a plan for what comes next.

Late Postmenopause (Ages 65 and Older)

Prolia's every-six-month dosing schedule suits women who prefer not to self-inject daily. The continuous antiresorptive effect accumulates over years, and the FREEDOM Long-Term Extensions showed continued BMD gains and low fracture rates out to 10 years in an open-label extension cohort. The main caveat is that stopping Prolia at any point requires transition to another antiresorptive within six months to prevent rebound vertebral fractures.

Premenopausal Women With Osteoporosis

Premenopausal osteoporosis is uncommon and almost always has a secondary cause: glucocorticoid use, anorexia, premature ovarian insufficiency, celiac disease, or other systemic conditions. Both Prolia and Tymlos are used off-label in premenopausal women in specific circumstances, but the evidence base in this group is thin. That is not a disclaimer added for legal cover; it reflects a genuine data gap that your clinician should name explicitly.

Pregnancy, Lactation, and Contraception: Read This Before You Start Either Drug

Both denosumab and abaloparatide are contraindicated in pregnancy. Women of reproductive age who could become pregnant must use reliable contraception throughout treatment.

Denosumab in Pregnancy

Denosumab crosses the placenta and has produced fetal bone abnormalities, absent lymph nodes, and other developmental effects in animal studies at doses comparable to human exposure. The FDA labeling for denosumab assigns it a category consistent with fetal harm risk and states that pregnancy outcomes should be monitored through the Amgen pregnancy surveillance program. There is no adequate data in pregnant women. Because denosumab has a half-life of approximately 26 days and the drug effect persists for about 6 months, women planning pregnancy should ideally stop the drug and allow full clearance before conception, though the clinical guidance here is nuanced and should be individualized.

Abaloparatide in Pregnancy

Animal reproductive studies with abaloparatide showed maternal and fetal toxicity. The abaloparatide prescribing information states the drug should not be used in pregnancy. Human data are essentially absent.

Lactation

Neither drug has adequate human lactation data. Both should be avoided during breastfeeding until more information is available. If a woman on Prolia delivers unexpectedly, the decision to breastfeed versus continue the drug requires a shared discussion with her clinician weighing individual fracture risk against infant exposure uncertainty.

Contraception Requirement

Any woman of reproductive potential starting either drug should use effective contraception. For Prolia, the long pharmacodynamic tail means contraception should continue until a clinician confirms it is safe to attempt conception. For Tymlos, daily dosing ends at 24 months maximum, and contraception should be in place throughout that window.

Who This Is Right For: A Life-Stage Decision Tree

Choosing between these two drugs is not a simple efficacy question. It is a life-stage, logistics, and individual-risk question.

Tymlos May Be the Better Starting Point If You:

• Are newly postmenopausal (within 10 years of menopause) with a T-score below minus 2.5 and at least one prevalent vertebral fracture
• Have very high fracture risk on FRAX and need fast BMD gains
• Have not yet tried an antiresorptive, making you an anabolic-first candidate per The Endocrine Society's clinical practice guideline on osteoporosis
• Can commit to daily self-injection for up to 24 months and have a follow-on plan

Prolia May Be the Better Fit If You:

• Are older postmenopausal (typically over 65) and prefer twice-yearly injections from your clinician
• Have already completed a course of anabolic therapy and need ongoing antiresorptive maintenance
• Have chronic kidney disease (mild to moderate), where bisphosphonates are less well tolerated and Prolia has data supporting use
• Need long-term continuous therapy without a built-in stopping clock

Neither Drug Is Appropriate If You:

• Are pregnant or planning pregnancy in the near term
• Have hypocalcemia (both drugs worsen it; calcium and vitamin D must be optimized first)
• Have Paget's disease of bone or prior skeletal radiation (Tymlos specifically carries a black box warning about osteosarcoma risk in these settings)

Side Effects: Where the Profiles Diverge

Denosumab Side Effects

The most clinically significant adverse events with denosumab include:

• Hypocalcemia. Seen in approximately 2% of patients in FREEDOM, but higher in women with vitamin D deficiency. Calcium and vitamin D optimization before starting is not optional.
• Serious infections. Skin infections (cellulitis) occurred in 0.4% of denosumab patients versus 0.1% placebo in FREEDOM.
• Atypical femoral fracture and osteonecrosis of the jaw. Both are rare but increase with prolonged use beyond 5 to 10 years, similar to bisphosphonates. The American Society for Bone and Mineral Research task force recommends surveillance.
• Rebound vertebral fractures on discontinuation. Multiple case series document rapid, sometimes multiple vertebral fractures within 6 to 18 months of stopping Prolia without a bridging antiresorptive.

Abaloparatide Side Effects

• Hypercalcemia. Less common than with teriparatide in the ACTIVE trial, but serum calcium should be monitored.
• Nausea, dizziness, palpitations. Typically transient and most common in the first weeks.
• Injection-site reactions. Mild erythema and pain; less common than with teriparatide.
• Osteosarcoma black box warning. Based on rat studies at high doses. The absolute risk in humans appears very low; no cases of osteosarcoma were identified in the ACTIVE trial or ACTIVExtend. Still, the label restricts use to 24 months lifetime maximum and contraindicates use in patients with open epiphyses, Paget's disease, prior radiation involving the skeleton, or bone metastases.

Switching Between the Two Drugs: What the Evidence Supports

Switching From Prolia to Tymlos

This sequence is less common and not straightforwardly supported. Women stopping Prolia face rebound bone loss; starting Tymlos after Prolia has been studied in small cohorts. One concern is that the antiresorptive withdrawal effect may partially blunt the anabolic response. If a switch is planned for clinical reasons, a bridging bisphosphonate is often inserted first, then Tymlos can follow.

Switching From Tymlos to Prolia

This is the more common and evidence-supported sequence. After completing 24 months of Tymlos, transitioning immediately to an antiresorptive preserves the BMD gains made during anabolic therapy. Denosumab is one reasonable follow-on option. The ACTIVExtend data used alendronate as the follow-on agent, showing that gains were durable at 43 months from original randomization.

Sequential Therapy Planning

Dr. Elena Vasquez, MD, WomanRx medical reviewer and women's-health specialist, frames it this way: "I think of Tymlos as laying the foundation and Prolia as sealing the roof. The sequence matters more than which drug is 'better.' A woman who needs bone built quickly should consider starting with an anabolic, then transitioning to a sustained antiresorptive. Choosing one drug in isolation, without the transition plan, is one of the most common clinical errors I see."

Dosing, Monitoring, and Practical Logistics

| Feature | Prolia (Denosumab) | Tymlos (Abaloparatide) | |---|---|---| | Dose | 60 mg subcutaneous every 6 months | 80 mcg subcutaneous daily | | Who administers | Clinician office injection | Self-injection (pen device) | | Duration limit | No formal cap; reassess at 5 to 10 years | 24 months lifetime maximum | | Monitoring | Calcium, vitamin D, creatinine at baseline; DXA every 1 to 2 years | Calcium, vitamin D at baseline; serum calcium if symptomatic; DXA after 18 months | | Cost without insurance | Approximately $1,300 to $1,500 per dose | Approximately $2,000 to $2,400 per month | | Patient assistance | Amgen SUPPORT program | Radius Health (now Theramex) assistance program |

Both drugs require adequate calcium and vitamin D before starting. The National Osteoporosis Foundation recommends 1,200 mg calcium daily for postmenopausal women (from diet plus supplement combined) and at least 800 to 1,000 IU vitamin D daily.

What the Evidence Gap Looks Like for Women

The osteoporosis trial literature is one of the few areas in cardiovascular and metabolic medicine where women are the primary study population, not an afterthought. FREEDOM and ACTIVE enrolled exclusively or predominantly postmenopausal women. That is genuinely good. The gaps that remain include:

• Premenopausal women with osteoporosis secondary to conditions like premature ovarian insufficiency or glucocorticoid use
• Perimenopausal women in the rapid bone-loss window
• Women with concurrent hormone therapy and either drug
• Transgender women on estrogen therapy (one area where data are nearly absent)

When your clinician extrapolates these trial results to a 48-year-old woman in early perimenopause with a T-score of minus 2.6, they are making a clinical judgment, not citing direct evidence. Ask them to name what is known versus what is estimated.

PCOS, Endometriosis, and Other Female Conditions

Women with PCOS who are anovulatory and estrogen-deficient over long periods face elevated fracture risk, though this is often underrecognized. Women with endometriosis treated with prolonged GnRH agonist therapy (like leuprolide) experience iatrogenic bone loss and may need pharmacologic bone protection. ACOG Committee Opinion 785 does not specifically address GnRH agonist-induced bone loss, but The Endocrine Society's guidelines note that add-back hormone therapy is preferred before pharmacologic bone agents in premenopausal women on GnRH agonists. If you have been on lupron or similar drugs for endometriosis and no one has checked your bone density, bring it up at your next visit.

Women with anorexia nervosa or a history of relative energy deficiency in sport (RED-S) may have severely low BMD before menopause, and the evidence for Prolia or Tymlos in this setting is limited. Restoration of energy availability and estrogen status is the first intervention; pharmacologic therapy is secondary and should be guided by a specialist.